Allowing the CAR-T cells to work upon the solid tumors can be a challenging task. CAR-T Congress EU organized in London by Kisaco Research stated that a team from the King’s College in London is working upon potent CAR-T cells that are known to react with some different targets in comparison to the one that has been approved recently to be used in cases of blood cancer.
John Maher –Leucid Bio’s Chief Scientific Officer & Clinical Senior Lecturer in the field of Immunology at King’s College, stated that the targeting of the CAR-T cells over a family of antigens referred to as “ErbB” could turn out to be highly powerful & reactive. As such, the team is prepared to inject the same directly into the cancer tumors for preventing further reactions with the surrounding healthy tissues.
After the Phase I clinical trials in cases of head and neck cancer that commenced in the year 2015, Maher reported that the observations obtained so far have suggested that CAR-T cells can be used in combination with the checkpoint inhibitors that have already received approval. As per the reports, the greatest strength of CAR-T treatment also turns out to be its greatest weakness. ErbB serves to be the family of receptors including HER-2 that already gets targeted by reputed cancer therapies. However, as the ErbB receptors can be expressed even in healthy tissues located in any other part of the body, there are higher chances of the occurrence of off-target reactions.
Through the direct injection of the CAR-T into the head and neck cancer tumors, Maher has observed that it helps in limiting the side effects of the treatment during the Phase I clinical trials of around 15 patients. On fronts of the overall safety, the given treatment appears viable. With the given treatment, the patients were able to tolerate the respective doses for up to the billion cells.
Some of the best responders of the treatment were successful in stabilizing the disease – around 9 cases. The study reveals that there is hope for the improved results of the study with respect to the overall survival. Maher reported that the team is looking for some type of combination. The combination could be with chemotherapy or with some blockade.
HOPE RISES With Us!